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Background: Certain antibiotics may cause unwanted side effects due to the similarity of the mitochondrial translation system to the prokaryotic
one. Children with cystic ﬁbrosis (CF) are vulnerable to recurrent respiratory tract infections and azithromycin, a translation targeted antibiotic, is
often used chronically to treat CF patients. No major clinical side effects were found with chronic treatment. However, mitochondrial function was
not previously assessed. We evaluated oxidative phosphorylation (OXPHOS) in lymphocytes from children with CF receiving chronic
azithromycin treatment using an improved ATP production assay.
Method: Enzymatic activities of respiratory chain complexes II–IV and ATP production were measured in lymphocytes.
Results: Relative to controls and to CF patients without azithromycin treatment, no signiﬁcant difference in mitochondrial respiratory chain
complexes II–IV was detected, and ATP production with pyruvate, glutamate and succinate, did not disclose any differences between the groups.
Conclusion: We suggest that chronic treatment with azithromycin does not signiﬁcantly affect OXPHOS function.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Azithromycin; Chronic treatment; OXPHOS; Mitochondrial respiratory chain1. Introduction
Cystic fibrosis (CF) is the most common life shortening
inherited disease in the population of European descent [1].
Mutations in the cystic fibrosis transmembrane conductance
regulator (CFTR) gene result in alteration in epithelial cell ion
transport leading to increased sputum viscosity, stasis of
secretions and impaired mucociliary clearance [2]. Dysregulation
of respiratory epithelial cells, and innate immune dysfunction in⁎ Corresponding author at: Department of Genetic and Metabolic Diseases,
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http://dx.doi.org/10.1016/j.jcf.2013.04.006the lung, leads to an exaggerated and ineffective airway
inflammation which fails to eradicate pulmonary pathogens [3,
4]. The increased viscosity of the sputum impairs the effective
clearance of inhaled microorganisms leading to recurrent
endobronchial infections and bacterial colonization, mainly
with Staphylococcus aureus and Pseudomonas aeruginosa, and
resulting in an exaggerated inflammatory response that leads to
the development of bronchiectasis and progressive obstructive
airway disease [5]. Though abnormal CFTR function results in
multi organ damage, the lung involvement has the most dramatic
impact on quality of life and survival [6]. In the late '80s, it was
shown that long term macrolide treatment substantially reduced
morbidity and mortality in patients with diffuse panbronchiolitis
[7, 8]. Since then, the potential benefit of macrolide antibioticsby Elsevier B.V. All rights reserved.
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including CF [9].
Macrolides belong to the group of translation targeted
antibiotic, interfering with protein synthesis, by reversibly
binding to the 50s subunit of prokaryotic ribosomes and inhibiting
the peptidyl transferase. The macrolide antibiotics achieve higher
tissue than plasma concentrations as they penetrate the respiratory
tissue and accumulate in the polymorphonuclear leukocyte
extremely well [10]. Given their favorable bioavailability via
oral route, their excellent tissue penetration and broad efficacy
against many organisms affecting the lung, macrolides are used as
first-line agents in the therapy of respiratory infections.Moreover,
macrolides have documented to have wide spectrum of
immunomodulatory effects on mammalian cells both in vivo
and in vitro. These effects limit tissue damage by neutrophils,
decrease mucus viscosity, and suppress angiogenesis, and support
the rationale for using macrolide therapy for the treatment
of chronic inflammatory airway diseases [11, 12]. Cochrane
systematic review and meta-analysis of data from 10 clinical trials
provide evidence that long term macrolide therapy in CF patients
improves lung function, decreases frequency of pulmonary
exacerbations, significantly reduce the need for oral antibiotics
and improves nutritional status [13]. These studies have lead
many CF centers, including ours, to treat patients with oral
azithromycin. Macrolides are considered to be well-tolerated
antibiotics; however, they have been associated with reversible
ototoxicity [14], transaminitis and prolongation of the QT interval
[11]. The most common side effect observed with Macrolide use
is related to the GI tract and is thought to be a result of their ability
to mimic the effects of motilin (a gastrointestinal tract polypeptide
hormone) [10]. In the previously mentioned trials with CF
patients, adverse events were uncommon and not obviously
associated with azithromycin [9, 15–19].
Azithromycin along with many other antibiotics is targeted
against the bacterial ribosome while sparing the eukaryotic
translation system, as the cytoplasmic ribosome has a somewhat
different structure. Contrarily, the mitochondrial translation
system is separate from the cytosolic, resembling the prokaryotic,
and the mitochondrial ribosome is more similar to the bacterial
one [20]. Therefore it is not surprising that they can be affected by
translation targeted antibiotics. In fact, side-effects such as
ototoxicity, liver dysfunction and QTc prolongation can be a
result of mitochondrial dysfunction [21]. Mitochondria are
intracellular organelles, providing the vast majority of cellular
energy in the form of ATP by oxidative phosphorylation
(OXPHOS). The OXPHOS system, consist of the four respiratory
chain complexes, consisting the electron transport chain (ETC)
and the fifth complex ATP synthase. All complexes, with the
exception of complex II, contain subunits encoded in the
mitochondrial DNA (mtDNA) and are therefore dependent on
intra-mitochondrial translation and the mitochondrial ribosome
[22].
Hereto forth the effect of translation targeted antibiotics on
mitochondrial function has been the subject of investigation in
vitro but to our knowledge, it has not been systematically
evaluated in children, and it is the objective of this study. As
most children with CF in our CF center are chronically treatedwith azithromycin as immunomodulator, we decided to focus
our investigation on this group of patients. Since long term
azithromycin treatment in CF patients infected with pseudo-
monas is becoming common, physician would benefit from an
evaluation of such possible side effect. The mitochondrial
function was evaluated in blood lymphocytes by measuring the
enzymatic activity of the ETC complexes and by measuring
ATP production by an improved method allowing minimal
sample size.
2. Subjects, materials and methods
2.1. Subjects
The study was done in the Hadassah medical center and
approved by the IRB ethics committee. Exclusion criteria were
refusal of the patient or his guardian, known mitochondrial
disease, infection or malignancy. Blood samples were obtained
by venipuncture with informed consent. Notably, For the CF
patients, blood samples were drawn in conjunction with other
periodic lab testing and no separate venipuncture was needed.
Usual concomitant therapy, including physiotherapy, inhaled
medications and pancreatic and vitamin supplements, continued
throughout the trial and was monitored by the clinic physicians.
2.2. Materials
Lymphoprep (Axis-Shield, Oslo, Norway) DMEM and fetal
calf serum (Biological Industries, Kibbutz Beit Haemek, Israel),
ATPlite (Perkin-Elmer Inc., USA), digitonin (Calbiochemicals,
San-Diego USA) all other chemicals were of highest possible
grade (Sigma-Aldrich USA).
2.3. Lymphocyte preparation
Lymphocytes were prepared from 3–5 ml blood (drawn in
EDTA) by differential centrifugation using Lymphprep (Axis-
Shield Norway) according to the manufacturers' instructions.
The lymphocyte suspension was divided into 2 aliquots in
Eppendorf tubes and pelleted by centrifugation 1 min
10.000 rpm in a microfuge. The supernatant was removed and
one batch was stored at −70 °C for enzymatic assays. The other
batch, for ATP production, was suspended in 0.5 ml freezing
medium (glucose free DMEM supplemented with 40% fetal calf
serum and 10% DMSO) placed in a freezing container (Mr.
Frosty, Nalgene, Thermo Fischer Scientific Inc.), frozen at −
70 °C overnight and subsequently transferred for extended
storage, into liquid nitrogen.
2.4. Enzymatic assays
Enzymatic activities of complexes II–IV in lymphocyte
homogenates were determined by spectrophotometry essentially
as described [23–25]. Briefly, Complex II was measured as
succinate dehydrogenase (SDH) based on the succinate-mediated
phenazine methosulfate reduction of dichloroindophenol at
600 nm. Complex II + III wasmeasured as succinate cytochrome
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Fig 1. ATP production in lymphocytes isolated from stored blood. Lymphocytes
from blood from a healthy adult control was isolated and frozen in freezing
medium, immediately or after different time periods of storage at room
temperature. Subsequently to storage in liquid nitrogen, the lymphocytes were
assayed for mitochondrial ATP production capability with the different substrates;
pyruvate + malate (PM), glutamate + malate (GM) or succinate (S). The
results are presented as mean ± SEM of at least triplicate measurements.
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550 nm. Complex IV (cytochrome c oxidase) was measured by
following the oxidation of reduced cytochrome c at 550 nm.
Citrate synthase (CS), an ubiquitous mitochondrial matrix
enzyme, serving as a control, was measured in the presence of
acetyl CoA and oxaloacetate by monitoring the liberation of
CoASH coupled to dithiobis (2-nitrobenzoic) acid at 412 nm.
Protein concentration was determined by the Lowry method and
calculated according to bovine serum albumin (BSA) standard
curve. Measurements were performed on a dual beam UVKON
spectrophotometer (Secomam, France).
2.5. ATP production
ATP production was determined as described by Berger
et al. [25] with the following modifications: lymphocytes were
rapidly thawed by adding 1 ml phosphate buffered saline (PBS)
and the suspension was microfuged for 1 min at 7000 rpm; the
pellet was washed once with 1.5 ml permeabilization-substrate-
mix buffer (potassium phosphate buffer 100 mM pH 7.4, KCl
150 mM, Tris25 mM pH 7.4 EDTA 2 mM, BSA fatty acid free
0.025%, ADP 1 mM, digitonin 40 μg/ml). The pellet was
resuspended in 0.35 ml permeabilization-substrate-mix buffer
and the reaction was started by adding 25 μl suspension to 25 μl
permeabilization-substrate-mix buffer containing the substrates
reaching the final concentrations of pyruvate 5mM + malate
1 mM (PM) or glutamate 5 mM + malate 1 mM (GM) or
succinate 10 mM in the presence of 5 μg/ml rotenone (S). After
an incubation of 30 min at 37 °C, the reaction was stopped by
adding 25 μl ATPlite cell lysis solution (for background readings
the cell lysis solution was added prior to the substrate). After
5 min shaking 50 μl was transferred to a white microtiter well
plate and 20 μl substrate solution was added, after 10 min dark
adaptation luminescence was read on a Synergy HT instrument
(BioTek, USA).
ATP production was calculated by comparing to a standard
curve which was constructed on each separate occasion.
2.6. Statistics
Data are expressed as mean ± SEM, and the results were
evaluated by one-way ANOVA to compare means using the
IBM SPSS statistics program version 20.
3. Results
3.1. Characteristics of the subjects
The study group consisted of 16 pediatric patients (12 years ±
4.4 years) diagnosed with CF treated with azithromycin 250 mg
(below 36 kg body weight) and 500 mg (above 36 kg of weight)
once a day for at least 3 years. The three control groups consisted
of 29 normal adult samples, 14 pediatric samples (obtained from
children visiting the outpatient clinics for various reasons but
without any signs of infections, malignancy, CF or mitochondrial
disorders), and from 5 children with CF but not treated with
azithromycin.3.2. Evaluation of ATP production assay
Initially we evaluated an improved version of the ATP
production assay that we have previously utilized for studying
the effect of anti epileptic drugs (Berger et al.). The major
drawback with the initial method was the instability of the
samples at −70 °C. The gradual decrease of temperature and
storage in liquid nitrogen, in the present study allowed the
frozen lymphocytes to retain the ATP producing capacity for at
least 6 months (results not shown). The ATP producing
capability in lymphocytes was also stable in lymphocytes isolated
from blood stored at room for up to 8 hours until lymphocyte
preparation allowing the sample to be transported to the
laboratory from the clinic. Immediate processing yielded a
somewhat higher capacity while an overnight 15h delay between
the blood drawing and lymphocyte preparation resulted in a
severe drop in ATP production. Therefore, all samples in this
study were processed between 4 and 8 hours (Fig. 1). The use of
ATPlite in combination with microtiter well reader facilitated and
shortened the assay process to less than 1 hour and allowed
triplicate repeats with all substrates from a single batch of
lymphocytes originating from 1.5 to 2 ml blood.
3.3. Mitochondrial function in patient and controls
Lymhocyte ATP production capability with all substrates
was not significantly different in patients chronically treated
with azithromycin compared to the normal adult and pediatric
control groups (Fig. 2). Rather ATP production was somewhat
increased with pyruvate + malate and glutamate + malate rela-
tive to the pediatric control and the untreated CF groups. From
the above data, we concluded that mitochondrial ATP production
capability in lymphocytes is clearly not, negatively affected by
chronic azithromycin treatment. On the other hand, the untreated
CF group was slightly but not statistically significant decreased
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Fig. 2. ATP production in lymphocytes from patients and controls. Lymphocytes
from blood from healthy adult controls (control adult), control pediatric patients
(control ped) pediatric CF patients (CF) and pediatric CF patients chronically
treated with azenil (CF az) and control were assayed for mitochondrial ATP
production capability with different substrates; pyruvate + malate (PM),
glutamate + malate (GM) or succinate (S). The results are presented as mean ±
SEM of at least triplicate measurements in each subject. *p b 0.05.
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Fig. 3. Enzymatic assay of ETC complexes. Lymphocytes from blood from
healthy adult controls (control adult), control pediatric patients (control ped)
pediatric CF patients (CF) and pediatric CF patients chronically treated with
Azenil (CF az) and control were assayed for enzymatic activities of ETC
complexes II–IV. Succinate dehydrogenase (SDH), succinate-cytochrome c
reductase (II + III), cytochrome c oxidase (COX) and the matrix control
enzyme citrate synthase. Fig. 3A depicts the actual activities while Fig. 3B depicts
the relative activities compared to citrate synthase. The results are presented as
mean ± SEM. *p b 0.05.
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could be drawn due to the small sample size and large SEM.
Notably the adult control group was not significantly different
from pediatric control group; therefore normal adult control
samples (which are more readily available than normal pediatric
samples) will be suitable as controls in future studies (Fig. 2).
The ATP production assays were complemented with
enzymatic measurements of individual ETC complexes. CS
served as an internal control and estimation of mitochondrial
content. Mitochondrial content was significantly increased in
the pediatric controls relatively to the adult controls and both CF
groups were decreased relatively the pediatric controls. However
there was no significant difference between CF patient treated or
not treated with Azenil. This was also reflected, but to a lesser
extent in COX activity but not in II + III or SDH activities
(Fig. 3A). The decrease in COXwas diminished when normalized
to citrate synthase activity. The II + III and SDH activities were
slightly increased in the CF groups (Fig. 3B). Taken together no
adverse effect of chronic azithromycin treatment on the measured
parameters was observed.4. Discussion
Several studies have shown the beneficial effect of long term
azithromycin treatment on the clinical status of cystic fibrosis
patients. Chronic treatment with azithromycin for CF patients
especially those infected with P. aeruginosa was shown to
improve lung function, to improve quality of life, to decrease
pulmonary exacerbation rate and to reduce the need for hospital
admissions and for antibiotic treatment. These trials did not
report major adverse events related to long term therapy. These
trials evaluated clinical status only; neither of them evaluated
the effect on mitochondrial function.The concern from chronic treatment with azithromycin for CF
patients has been the possible inhibitory influence of macrolides
on the DNAse activity as seen in vitro, since most of the CF
patients are treated with DNAse [11]. Another concern which still
needs to be proven by designated research is the emergence of
macrolide resistance strains of S. aureus but there is lack of long
term data [13].
Drug induced mitochondrial toxicity is gaining recognition
within the pharmaceutical industry; there are some in vitro
methods for assessment of mitochondrial damage but to date
there is lack of validated biomarkers for identifying drug
induced mitochondrial dysfunction in patients [26]. Notably,
some of the biochemical parameters of mitochondrial damage
can mimic CF exacerbation or an acute infection in a CF patient
(lactic acidosis, raised urea and creatinine, raised liver enzymes
and hypo/hyperglycemia). Our research is a pilot assessment of
the mitochondrial function in patients chronically treated with
azithromycin. The mitochondrial OXPHOS was measured by
686 S.B.-H. Negari et al. / Journal of Cystic Fibrosis 12 (2013) 682–687two parameters in the peripheral lymphocytes; enzymatic activity
of the respiratory chain complexes II–IV and ATP production.
The improved freezing technique and storage in liquid
nitrogen allowed reproducible ATP production after up to eight
hour delay before lymphocyte preparation and prolonged storage
in liquid nitrogen. The use of ATPlite kit with microtiter plates
was much more convenient than the previous assay [25]. The
improved method facilitates future studies allowing comparative
measurement of ATP production in repeated samples from the
same individual taken at different time intervals and transported
from distant clinics.
The ATP production assays were complemented by enzymatic
measurements of the individual ETC complexes. We were not
able to accurately measure rotenone sensitive complex I activity
(despite numerous efforts), due to interfering NADH dehydro-
genases in the homogenate. Notably mitochondrial isolation from
small blood samples is not feasible. Nevertheless ATP production
from both pyruvate and glutamate is complex I dependent
and sufficient to detect complex I defects [23]. Moreover ATP
production from pyruvate is proportional to pyruvate dehydro-
genase activity [27].
Lymphocytes isolated from patients and control groups were
analyzed with the improved ATP production method as well as
with the enzymatic assays.
Taken together, the results disclosed no significant effect of
chronic azithromycin treatment on mitochondrial function in
children with CF was detected. Rather some parameters were
improved compared to untreated patients. Regretfully as the
majority of CF patients in our center are treatedwith azithromycin,
we were not able to include more non-treated CF patients in this
study to confirm the significance of this observation with respect to
ATP production. CSmeasured in lymphocyte homogenate showed
a moderate but significant decrease in mitochondrial content
observed in all patients relative to pediatric controls. This seems to
be related to CF per se and not azithromycin as both treated and
non-treated patients showed the same decrease. Nevertheless this
decrease did not affect the overall OXPHOS as measured by ATP
production. These results are in accord with our pervious results
data, showing that azithromycin did not significantly affect
OXPHOS dependent control fibroblast cell growth while exerting
only a modest effect on fibroblasts derived from patients with
mitochondrial translation disorders. On the contrary, chloram-
phenicol, impaired growth of both control and patients cells, even
though both antibiotics bind to the exit tunnel of the prokaryotic
large ribosomal subunit. Moreover, azithromycin, a macrolide,
affects in-vitro mitochondrial translation; it does so to a much
lesser extent than other classes of translation targeted antibiotics
such as the aminoglycoside gentamycin and the tetracycline
derivative doxycycline [28]. The variations between the antibi-
otics are most probably due to minor differences between the
mitochondrial and the prokaryotic ribosome aswell as their ability
to penetrate cell membranes. Taken together, the data suggest that
azithromycin is relatively harmless to mitochondrial function, and
we therefore conclude that chronic treatment with azithromycin
does not significantly impair OXPHOS function in lymphocytes.
Further investigation is warranted in a larger cohort and ,in other
tissues to confirm our data [29].Conﬂict of interest
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